← Go back

Date of filling in this questionnaire or last update: 04/03/2021
1. IDENTIFICATION & BASIC DESCRIPTION
Cohort name
  The PIPAH Study
Country
 

  • United Kingdom
Please provide any other information on the cohort location/s if needed
  Data collected in Great Britain (England, Scotland, and Wales)
Name
  Anne-Helen Harding
Institution
  Health and Safety Executive
Email
  anne-helen.harding@hse.gov.uk
Website
 

  • https://www.hsl.gov.uk/resources/major-projects/pipah
Name of committee
  Health Research Authority Natational Research Ethics Service Committee North West - Great Manchester North
Or provide website
 

  • https://www.hsl.gov.uk/resources/major-projects/pipah
Contact Principal Investigator (name)
  Anne-Helen Harding
Is this cohort part of a consortium? (name consortium)
  AGRICOH
Participation in pooled analyses
 

  • The cohort is potentially interested in participating in pooled analyses of (European) occupational cohort studies (note pooled analyses also includes remote decentralized analyses that would not require any transfer of primary data as well as meta-analyses).
Main aim of cohort, please briefly describe the main objectives of the cohort
  The main aim of the study is to monitor the exposure and health of workers in Great Britain who use pesticides as a part of their job, and to investigate the association between chronic exposure to pesticides and health.
Study design (please select as many as appropriate)
 

  • Prospective cohort
Source population (please select as many as appropriate)
 

  • Industry / occupation-based
Comparators (please select as many as appropriate)
 

  • Internal study population
  • External comparison of workers with other exposure
  • External study population (includes SMR/SIR studies)
Inclusion criteria
  Professional pesticide users working in Great Britain who are members of the National Register of Sprayer Operators (NRoSO), the National Amenity Sprayer Operators' Register (NAsOR), or the Pesticide Users' Health Study (PUHS)
Exclusion criteria
  Not a member of one of the above groups; not resident in Great Britain
Enrollment
  Ongoing
Age range at entry (main cohort)
 

Minimum Maximum Mean
19 >65 54

Men at enrollment
  5547
Women at enrollment
  126
Children (<18 years) at enrollment
  0
Men at last follow-up
  4709
Women at last follow-up
  111
Children (<18 years) at last follow-up
  0
Participation rate at enrollment (if known)
  20
2. OUTCOME FOLLOW-UP
Type of data for outcome follow-up (please select as many as appropriate)
 

  • Active (contact with participants)
  • Death certificate
  • Use of registers (specify)
Active (contact with participants) (specify)
 

  • Participants are contacted every year and invited to complete a follow-up questionnaire. A study newsletter accompanies this request.
Death certificate (specify)
 

  • Participants are flagged with the National Health Service Central Registers so that we are notified of any deaths amongst the study participants
Specify: Use of registers
 

  • Participants are flagged with the National Health Service Central Registers so that we are notified of any cancers recorded for the study participants on the Cancer Registries
First follow-up period (provide year)
  2014
Last follow-up period (provide year)
  2021
Number of follow-ups after baseline (provide number)
  8
Comments
  The 2021 follow-up is on-going and we do not yet know what the response rate will be. The response rate in 2020 was 45%.
3. OCCUPATIONAL EXPOSURES
Source of exposure data collected (please select as many as appropriate)
 

  • Questionnaire, Personal (Occupational/industry modules)
  • Job calendar
Occupational history/time frame
  Lifetime
Occupational coding performed
  No
Main categories
 

  • Pesticides
Comments
  The study participants use pesticides as a part of their job, and this is the main focus. Most participants are farmers, and most participants will be affected to some extent by virtually all of the other main categories of exposure listed above.
4. OUTCOMES EVALUATED
Baseline - type of outcome data collected (select more than one if applicable)
 

  • Death certificates
  • Questionnaire, individual (self-recording or interview)
  • Registry-based
Registry-based
 

  • Cancer incidence
  • Mortality register
Follow-up - type of outcome data collected (select more than one if applicable)
 

  • Death certificates
  • Questionnaire, individual (self-recording or interview)
  • Registry-based
Registry-based
 

  • Cancer incidence
  • Mortality register
Outcome type (please select as many as appropriate)
 

  • Mortality
  • Morbidity
Diagnostic groups based on ICD10
 

  • C + D Neoplasms
  • E Endocrinological disease
  • F Mental disorders
  • G Disease in the nervous system
  • H Disorders of the eye
  • I Heart disease
  • I Cerebrovascular diseases
  • J Respiratory disease
  • K Diseases of peritoneum, liver
  • L Skin, nail and hair disorders
  • M Disorders of muscles, bones, synovialis, bursa, cartilage
  • N Kidney, renal pelvis disease
C + D Neoplasms
 

  • Benign neoplasm
  • Carcinoma in situ
  • Leukemia
  • Malignant neoplasms gastro intes. system including liver, gall bladder, pancreas
  • Malignant neoplasm lung
  • Mesothelioma
  • Other malignant neoplasm of respiratory and intrathoracic organs, heart, pleura
  • Malignant neoplasm of bone and articular cartilage
  • Melanoma and other malignant neoplasms of skin
  • Neoplasms connective and soft tissue including nerves
  • Malignant neoplasm of breast
  • Malignant neoplasms, females gynecological
  • Malignant neoplasms of male genital organs
  • Malignant neoplasm of urinary tract and kidney
  • Malignant neoplasms of eye, brain and other parts of central nervous system
  • Malignant neoplasms of thyroid and other endocrine glands
  • Malignant neoplasms of ill-defined, secondary and unspecified sites
  • Malignant neoplasm without specification of site including excl. leukemia
E Endocrinological disease
 

  • Diabetes mellitus
  • Other, please state
E Endocrinological disease | Other (specify)
  Goitre, Thyrotoxicosis, and 'other' endocrine disorders (specify)
F Mental disorders
 

  • Dementia
  • Depression
  • Other, please state
F Mental disorders | Other (specify)
  Work related stress, 'other' mental health problems (specify)
G Disease in the nervous system
 

  • Parkinson's disease
  • Alzheimer's disease
  • Multiple sclerosis
  • Epilepsy
  • Other, please state
G Disease in the nervous system | Other (specify)
  Motor neuron disease, 'other' diseases of nervous system (specify)
H Disorders of the eye
 

  • Senile cataract
  • Other cataract
  • Retinal disorders
  • Glaucoma
  • Other, please state
H Disorders of the eye | Other (specify)
  Macular degeneration; Ocular melanoma
I Heart disease
 

  • Hypertensive diseases
  • Angina pectoris
  • Acute myocardial infarction
  • Other, please state
I Heart disease | Other (specify)
  Peripheral vascular disease, arrhythmia
I Cerebrovascular diseases
 

  • Subarachnoid haemorrhage
  • Intracerebral haemorrhage
  • Cerebral infarction
  • Stroke, not specified as haemorrhage or infarction
J Respiratory disease
 

  • Viral pneumonia
  • Bacterial pneumonia
  • Chronic Bronchitis
  • Emphysema
  • Chronic obstructive pulmonary disease (COPD)
  • Asthma
  • Pneumoconiosis
  • Other, please state
J Respiratory disease | Other (specify)
  Mesothelioma, lung cancer, pleurisey, sarcoidosis, tuberculosis, 'other' chest condition
K Diseases of peritoneum, liver
 

  • Other, please state
K Diseases of peritoneum, liver | Other (specify)
  Liver cancer, liver function problems (specify)
L Skin, nail and hair disorders
 

  • Allergic contact dermatitis
  • Irritant contact dermatitis
  • Acne
  • Other, please state
L Skin, nail and hair disorders | Other (specify)
  shingles, skin cancer, 'other' skin problems (specify)
M Disorders of muscles, bones, synovialis, bursa, cartilage
 

  • Other, please state
M Disorders of muscles, bones, synovialis, bursa, cartilage | Other (specify)
  Lupus, rheumatoid arthritis, scleroderma, work-related back, neck or shoulder injury, 'other' connective tissue disorder (specify)
N Kidney, renal pelvis disease
 

  • Renal failure
  • Other, please state
N Kidney, renal pelvis disease | Other (specify)
  pyelonephritis, kidney stones, nephritis/nephrosis, kidney cancer, 'other' kidney disease (specify)
Other health related outcomes
 

  • Quality of life/wellbeing
  • Work participation
  • Other (specify)
Specify: Other
  In follow-up questionnaire, EQ5D and UK ONS Personal well-being questions included
Comments
  Collected information on family medical history
6. Other Information
 

  • Alcohol
  • Demographics
  • Diet
  • Education
  • Medical history
  • Physical exercise
  • Socioeconomic status
  • Smoking
Possibility for linkage to data registries/data enrichment via data linkage
 

  • Hospital discharge
Please describe plans that are funded or most likely to be funded
  The plan is to continue sending the study members an annual questionnaire.